Novadaq Technologies (NVDQ) was Upgraded by Feltl & Co. to ” Strong Buy”. Earlier the firm had a rating of “Buy ” on the company shares. Feltl & Co. advised their investors in a research report released on Jul 28, 2016.
On the company’s financial health, Novadaq Technologies reported $-0.29 EPS for the quarter, missing the analyst consensus estimate by $ -0.15 based on the information available during the earnings call on Jul 27, 2016. Analyst had a consensus of $-0.14. The company had revenue of $20.12 million for the quarter, compared to analysts expectations of $19.97 million. The company’s revenue was up 33.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.22 EPS.
Novadaq Technologies opened for trading at $10.92 and hit $10.92 on the upside on Thursday, eventually ending the session at $10.26, with a gain of 16.19% or 1.43 points. The heightened volatility saw the trading volume jump to 17,30,354 shares. Company has a market cap of $589 M.
Novadaq Technologies Inc. develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Company’s imaging platform can be used to visualize blood vessels nerves and the lymphatic system during surgical procedures. The Company generates revenues from the sale of medical devices and consumables capital devices or consumable products the rental of capital devices royalties upfront payments received from partners for exclusive sales and marketing rights and extended warranty services agreements in connection with capital sales. The Companys SPY imaging products are SPY Elite FIREFLY LUNA PINPOINT CO2 HEART LASER systems and DermACELL Advanced Decellularized Dermis. The SPY Imaging System is United States Food and Drug Administration (FDA) cleared for use in seven surgical specialties including coronary artery bypass cardiovascular plastic reconstructive micro organ transplant and gastrointestinal surgery.